logo
A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism
Bleeding risk in randomized controlled trials comparing warfarin and aspirin
Reversal of the anti-platelet effects of aspirin and clopidogrel
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety
Genetic admixture is associated with plasma hemostatic factor levels in self-identified African Americans and Hispanics
Genetic determinants of von Willebrand factor plasma levels and the risk of stroke
Coronary artery bypass graft surgery up-regulates genes involved in platelet aggregation
Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs
D-dimer threshold increase with pretest probability unlikely for pulmonary embolism to decrease unnecessary computerized tomographic pulmonary angiography
D-dimer testing in the diagnosis of cerebral vein thrombosis
INR targets and site-level anticoagulation control
Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders
Demographic and clinical data in acquired hemophilia A
Different bleeding risk in type 2A and 2M von Willebrand disease
The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus
Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid-like structures and activate platelets via glycoprotein IIb/IIIa
Diurnal expression of the thrombopoietin gene is regulated by CLOCK
The profibrotic cytokine transforming growth factor-β1 increases endothelial progenitor cell angiogenic properties
Circulating microparticles and endothelial progenitor cells in atherosclerosis
Periprocedural antithrombotic and bridging therapy
Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis
Darexaban has high sensitivity in the prothrombin time clotting test
Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction
Psoriasis is associated with a greater risk of incident venous thromboembolism
Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage
Discrepancy of the international normalized ratio observed in the external quality assessment survey
Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents
Genetic variation in F3 (tissue factor) and the risk of incident venous thrombosis
Factor XIII plasma levels in women with unexplained recurrent pregnancy loss
Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors
von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura
Heparin concentrations in neonates during cardiopulmonary bypass
Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis
Join ISTH
Corrigendum